The findings presented here support a model in which A3B expression is universally repressed during cellular dormancy (i.e., G0 and G1 phases), whereas pathway activation during the proliferative stage (G2 and M phases) contributes to the overexpression of A3B found in a subset of breast cancer cell lines and tumors. Here, APOBEC3B is linked to breast cancer.